Replication defective adenovirus vector in vaccination

1. A composition comprising a single dose of a pharmaceutical composition comprising from 1×10 9 to 5×10 11 viral particles of a replication-defective vector comprising a nucleic acid sequence encoding an amino acid sequence according to SEQ ID NO:5.

2. The composition of claim 1 , wherein the replication-defective vector is a replication-defective adenoviral vector.

3. The composition of claim 2 , wherein the replication-defective adenoviral vector has a deletion in an early 2b (E2b) gene region.

4. The composition of claim 3 , wherein the replication-defective adenoviral vector further comprises a deletion in an early 1 (E1) gene region, a deletion in an early 3 (E3) gene region, a deletion in an early 4 (E4) gene region, or a combination thereof.

5. The composition of claim 1 , wherein the single dose of the pharmaceutical composition comprises a dose of at least 10 9 replication-defective viral particles.

6. The composition of claim 1 , wherein the single dose of the pharmaceutical composition comprises a dose of at least 10 11 replication-defective viral particles.

7. The composition of claim 1 , further comprising an additional composition.

8. The composition of claim 7 , wherein the additional composition comprises an immunostimulant.

9. The composition of claim 7 , wherein the additional composition comprises a vector encoding an antigen selected from p53, HPV E6, HPV E7, MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, BAGE, DAM-6, -10, GAGE-1, -2, -8, GAGE-3, -4, -5, -6, -7B, NA88-A, NY-ESO-1, MART-1, MC1R, Gp100, PSA, PSM, Tyrosinase, TRP-1, TRP-2, ART-4, CAMEL, Cyp-B, Her2/neu, hTERT, hTRT, iCE, MUC1, MUC2, PRAME, P15, RU1, RU2, SART-1, SART-3, WT1, AFP, 13-catenin/m, Caspase-8/m, CEA, CDK-4/m, ELF2M, GnT-V, G250, HSP70-2M, HST-2, KIAA0205, MUM-1, MUM-2, MUM-3, Myosin/m, RAGE, SART-2, TRP-2/INT2, 707-AP, Annexin II, CDC27/m, TPI/mber-abl, ETV6/AML, LDLR/FUT, Pml/RARa, TEL/AML1, or any combination thereof.

10. The composition of claim 7 , wherein the additional composition further comprises a vector encoding an antigen selected from HPV E6, HPV E7, Her2/neu, MUC1, PSA, PSM, or any combination thereof.

11. The composition of claim 1 , wherein the pharmaceutical composition is formulated as an aerosol for delivery by intranasal spray or inhalation, as a powder for preparation of solutions or dispersions, in a pill for oral deliver, in a suppository for vaginal or rectal delivery, or in a polytetrafluoroethylene support matrix for transmucosal delivery.

12. The composition of claim 11 , wherein the solutions or dispersions are injectable by parenteral delivery via intravenous injection, intraperitoneal injection, subcutaneous injection, or intramuscular injection.

13. The composition of claim 1 , wherein the replication-defective vector is encapsulated in a lipid particle, a liposome, a vesicle, a nanosphere, or a nanoparticle.

14. The composition of claim 1 , wherein the replication-defective vector is covalently or non-covalently bound to a lipid particle, a liposome, a vesicle, a nanosphere, or a nanoparticle.

15. The composition of claim 1 , wherein the pharmaceutical composition comprises a dose of replication-defective vectors capable of promoting a target antigen immune response.

16. The composition of claim 1 , wherein the pharmaceutical composition comprises a dose of replication-defective vectors sufficient to provide a therapeutic benefit, a prophylactic benefit, or a combination thereof.

17. The composition of claim 7 , wherein the additional composition further comprises chemotherapy or a dose of radiation.

18. The composition of claim 17 , wherein the chemotherapy comprises fluoropyrimidine, irinotecan, oxaliplatin, bevacizunab, Capecitabine, Mitomycin, Regorafenib, cetuxinab, panitumumab, acetinophen, or any combination thereof.